HK1159686A1 - Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising same hla-a1101 wt1 - Google Patents

Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising same hla-a1101 wt1

Info

Publication number
HK1159686A1
HK1159686A1 HK12100169.1A HK12100169A HK1159686A1 HK 1159686 A1 HK1159686 A1 HK 1159686A1 HK 12100169 A HK12100169 A HK 12100169A HK 1159686 A1 HK1159686 A1 HK 1159686A1
Authority
HK
Hong Kong
Prior art keywords
hla
peptide
restricted
pharmaceutical composition
same
Prior art date
Application number
HK12100169.1A
Other languages
English (en)
Chinese (zh)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of HK1159686A1 publication Critical patent/HK1159686A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
HK12100169.1A 2006-12-28 2012-01-06 Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising same hla-a1101 wt1 HK1159686A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28

Publications (1)

Publication Number Publication Date
HK1159686A1 true HK1159686A1 (en) 2012-08-03

Family

ID=39588385

Family Applications (3)

Application Number Title Priority Date Filing Date
HK13100536.6A HK1173187A1 (zh) 2006-12-28 2012-01-06 -限制性 肽及含有其的藥物組合物
HK12100169.1A HK1159686A1 (en) 2006-12-28 2012-01-06 Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising same hla-a1101 wt1
HK16109237.6A HK1221252A1 (zh) 2006-12-28 2016-08-03 限制的 肽及含有其的藥物組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13100536.6A HK1173187A1 (zh) 2006-12-28 2012-01-06 -限制性 肽及含有其的藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16109237.6A HK1221252A1 (zh) 2006-12-28 2016-08-03 限制的 肽及含有其的藥物組合物

Country Status (28)

Country Link
US (4) US8653038B2 (fr)
EP (6) EP2479275B1 (fr)
JP (1) JP5484734B2 (fr)
KR (1) KR101525261B1 (fr)
CN (5) CN102659924B (fr)
AR (1) AR064555A1 (fr)
AU (1) AU2007340679B2 (fr)
BR (1) BRPI0720988A2 (fr)
CA (5) CA2886622A1 (fr)
CY (1) CY1116011T1 (fr)
DK (3) DK2479275T3 (fr)
ES (4) ES2556831T3 (fr)
HK (3) HK1173187A1 (fr)
IL (4) IL199052A0 (fr)
MX (1) MX2009007008A (fr)
MY (1) MY161664A (fr)
NO (1) NO20092774L (fr)
NZ (4) NZ601175A (fr)
PH (1) PH12014500902B1 (fr)
PL (1) PL2341142T3 (fr)
PT (1) PT2341142E (fr)
RU (1) RU2481398C2 (fr)
SG (1) SG177222A1 (fr)
SI (1) SI2341142T1 (fr)
TW (3) TWI599367B (fr)
UA (1) UA103154C2 (fr)
WO (1) WO2008081701A1 (fr)
ZA (1) ZA200903633B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
EP1951281B1 (fr) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
MX352947B (es) 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
SG10201508252PA (en) * 2010-10-05 2015-11-27 Int Inst Cancer Immunology Inc Method for activating helper t cell
AU2012236068A1 (en) * 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
KR20140083986A (ko) * 2011-09-14 2014-07-04 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 항wt1 항체의 측정 방법
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
RU2680588C2 (ru) 2012-09-12 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Гены рецепторов антигенспецифичных хелперных т-клеток
CA2894511C (fr) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Procedes pour identification de recepteur/ligand a rendement eleve
SG10201705028WA (en) * 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
HUE052541T2 (hu) 2013-01-15 2021-05-28 Memorial Sloan Kettering Cancer Center Immunogén WT-1 peptidek és eljárások azok alkalmazására
RU2014102939A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для чрескожного введения
CA2840959A1 (fr) 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin
JP2014169275A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 粘膜投与用ワクチン組成物
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CA2841016A1 (fr) 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin contre le cancer avec peptide wt1 pour administration transdermique
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
CA2840954A1 (fr) 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin pour administration transdermique ou muqueuse
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US10588952B2 (en) * 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
ES2691091T3 (es) 2013-03-29 2018-11-23 Sumitomo Dainippon Pharma Co., Ltd. Vacuna conjugada de péptido antigénico de WT1
US10525096B2 (en) 2014-12-11 2020-01-07 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
EP3458095A4 (fr) 2016-05-18 2019-11-27 Albert Einstein College of Medicine Variants de polypeptides pd-l1, polypeptides multimères modulateurs des lymphocytes t et procédés d'utilisation correspondants
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3558339B1 (fr) 2016-12-22 2024-01-24 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t et leurs méthodes d'utilisation
EP3565829A4 (fr) 2017-01-09 2021-01-27 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CN111741972A (zh) * 2017-12-27 2020-10-02 大日本住友制药株式会社 Wt1衍生肽的缀合物和包含其的组合物
WO2019139896A1 (fr) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
MX2022014249A (es) * 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
KR20230009872A (ko) 2020-05-12 2023-01-17 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
RU2237674C2 (ru) * 1998-09-30 2004-10-10 Корикса Корпорейшн Композиции и способы wt1-специфичной иммунотерапии
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CZ20013527A3 (cs) * 1999-04-02 2002-10-16 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
NZ521430A (en) * 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
ATE383375T1 (de) * 2001-03-22 2008-01-15 Int Inst Cancer Immunology Inc Wti-modifiziertes peptid
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
AU2003242305A1 (en) 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
AU2003245453B2 (en) * 2002-06-14 2008-08-14 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004063217A1 (fr) 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Peptide dimerise
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
ES2341785T3 (es) 2004-03-31 2010-06-28 International Institute Of Cancer Immunology, Inc. Peptidos antigenicos del cancer derivados de wt1.
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
WO2010037395A2 (fr) * 2008-10-01 2010-04-08 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer

Also Published As

Publication number Publication date
US20110098233A1 (en) 2011-04-28
TW200835513A (en) 2008-09-01
ES2629578T3 (es) 2017-08-11
EP2341142B1 (fr) 2014-11-26
CN102295682A (zh) 2011-12-28
CA2886620A1 (fr) 2008-07-10
IL215334A0 (en) 2011-11-30
NZ577443A (en) 2011-12-22
PH12014500902A1 (en) 2016-01-11
US20160199472A1 (en) 2016-07-14
ES2554775T3 (es) 2015-12-23
NZ601175A (en) 2012-12-21
TW201345544A (zh) 2013-11-16
EP2479276A1 (fr) 2012-07-25
JP5484734B2 (ja) 2014-05-07
EP3026115A1 (fr) 2016-06-01
EP2098595A4 (fr) 2010-03-17
MX2009007008A (es) 2009-07-10
NO20092774L (no) 2009-07-27
WO2008081701A1 (fr) 2008-07-10
IL199052A0 (en) 2010-03-28
US9272026B2 (en) 2016-03-01
CN102659924B (zh) 2015-11-25
CN102302788A (zh) 2012-01-04
CN101573448B (zh) 2012-07-11
EP2980219A1 (fr) 2016-02-03
CA2886621A1 (fr) 2008-07-10
PH12014500902B1 (en) 2016-01-11
ES2526425T3 (es) 2015-01-12
RU2481398C2 (ru) 2013-05-10
CN102659924A (zh) 2012-09-12
US20180064795A1 (en) 2018-03-08
EP2479275B1 (fr) 2015-10-28
UA103154C2 (uk) 2013-09-25
CY1116011T1 (el) 2017-01-25
CN102335439B (zh) 2015-04-22
DK2479275T3 (en) 2015-12-14
CA2886622A1 (fr) 2008-07-10
EP2980219B1 (fr) 2018-11-14
IL215333A0 (en) 2011-11-30
BRPI0720988A2 (pt) 2014-03-18
SI2341142T1 (sl) 2015-03-31
CN102335439A (zh) 2012-02-01
AU2007340679A1 (en) 2008-07-10
NZ592510A (en) 2012-11-30
HK1221252A1 (zh) 2017-05-26
JPWO2008081701A1 (ja) 2010-04-30
EP2341142A2 (fr) 2011-07-06
RU2009128979A (ru) 2011-02-10
ZA200903633B (en) 2010-02-24
KR20090102772A (ko) 2009-09-30
TWI554280B (zh) 2016-10-21
EP2479275A1 (fr) 2012-07-25
CN101573448A (zh) 2009-11-04
KR101525261B1 (ko) 2015-06-02
AU2007340679B2 (en) 2013-09-12
EP2341142A3 (fr) 2011-09-07
TWI599367B (zh) 2017-09-21
AR064555A1 (es) 2009-04-08
US8653038B2 (en) 2014-02-18
HK1173187A1 (zh) 2013-05-10
ES2556831T3 (es) 2016-01-20
CA2670658A1 (fr) 2008-07-10
DK2479276T3 (en) 2015-12-21
CN102302788B (zh) 2016-06-15
CA2886619A1 (fr) 2008-07-10
MY161664A (en) 2017-04-28
EP3026115B1 (fr) 2017-05-17
NZ592509A (en) 2012-11-30
EP2098595A1 (fr) 2009-09-09
EP2341142B8 (fr) 2015-01-14
EP2479276B1 (fr) 2015-12-09
IL215332A0 (en) 2011-11-30
US20140134200A1 (en) 2014-05-15
TWI417103B (zh) 2013-12-01
TW201630620A (zh) 2016-09-01
PT2341142E (pt) 2015-02-13
SG177222A1 (en) 2012-01-30
DK2341142T3 (en) 2014-12-08
PL2341142T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
HK1221252A1 (zh) 限制的 肽及含有其的藥物組合物
IL232408A0 (en) 3303 * a-hla – reduced 1wt peptide and pharmaceutical compound containing it
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
EP2056835A4 (fr) Compositions pharmaceutiques et leurs utilisations
EP1976864A4 (fr) Nouveau peptide et son utilisation
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
AP2008004571A0 (en) Peptide sequences and compositions
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
IL193700A0 (en) Medicaments and proteins
IL195525A0 (en) Replikin peptides and uses thereof
GB0610090D0 (en) Particulate drug compositions and their uses
EP2070919A4 (fr) Composé de spiroquinone et composition pharmaceutique
GB0604187D0 (en) Peptide and uses thereof
GB0614365D0 (en) Pharmaceutical compositions and their use
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
EP1937292A4 (fr) Compositions pharmaceutiques a base de lopap et leurs utilisations
EP2114404A4 (fr) Composé et composition pharmaceutiques
IL192800A0 (en) Fgf2-binding peptides and uses thereof
PL378824A1 (pl) Peptyd i jego zastosowanie
IL178937A0 (en) Pharmaceutical and cosmetic compositions
GB0612873D0 (en) Isolated peptides and uses thereof